Holen Sie sich die Stockscreener-App
1.10
5.17%
-0.06
Handel nachbörslich:
1.09
-0.01
-0.91%
Schlusskurs vom Vortag:
$1.16
Offen:
$1.15
24-Stunden-Volumen:
35,922
Relative Volume:
0.04
Marktkapitalisierung:
$1.47M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.28M
KGV:
-0.0791
EPS:
-13.91
Netto-Cashflow:
$-13.75M
1W Leistung:
-12.70%
1M Leistung:
-48.11%
6M Leistung:
-77.32%
1J Leistung:
-86.47%
1-Tages-Spanne:
$1.10
$1.1921
1-Wochen-Bereich:
$1.10
$1.2987
52-Wochen-Spanne:
$1.10
$9.25
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Firmenname
Pasithea Therapeutics Corp
Sektor
Branche
Telefon
(818) 422-6172
Adresse
2110 NARCISSUS CT, VENICE
Vergleichen Sie KTTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
1.10 | 1.47M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
KTTA stock touches 52-week low at $1.12 amid market challenges - Investing.com India
KTTA stock touches 52-week low at $1.12 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $1.24 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $1.24 amid market challenges By Investing.com - Investing.com South Africa
Pasithea's PAS-004 advances in cancer trial with no toxicities - MSN
KTTA stock touches 52-week low at $1.32 amid market challenges - Investing.com Nigeria
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update - Defense World
Pasithea Therapeutics Corp (KTTA) Stock: A Study of the Market Performance - The News Heater
An analyst sees good growth prospects for Pasithea Therapeutics Corp (KTTA) - SETE News
Daily Progress: Pasithea Therapeutics Corp (KTTA) Drop -21.90, Closing at 2.14 - The Dwinnex
Big Mid-Week Move From This Small Biotech - The Globe and Mail
KTTA stock touches 52-week low at $2.19 amid market challenges - MSN
Pasithea Therapeutics Corp (KTTA) Stock: Navigating Drops and Gains - The InvestChronicle
Understanding KTTA’s financial ratios: A beginner’s guide - US Post News
Pasithea (KTTA) Stock Spikes On Its Latest Clinical Trial Milestone - Stocks Telegraph
Pasithea Therapeutics Shares Rise After Positive Safety Review for Cancer Treatment - MarketWatch
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
Top Premarket Gainers -February 05, 2025 at 07:47 am EST - Marketscreener.com
Pasithea announces Safety Review Committee recommendation - TipRanks
Pasithea's PAS-004 advances in cancer trial with no toxicities By Investing.com - Investing.com UK
Pasithea Therapeutics Announces Positive Safety Review - GlobeNewswire
Clinical Trial Breakthrough: Cancer Drug Shows Unprecedented Safety Profile in Phase 1 - StockTitan
US Stocks Mixed; Walt Disney Posts Upbeat Earnings - Benzinga
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Up 37.2% in December - Defense World
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 - GlobeNewswire
Pasithea Therapeutics Corp. Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 - Marketscreener.com
KTTA stock touches 52-week low at $2.33 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $2.33 amid market challenges By Investing.com - Investing.com South Africa
Analyzing Galecto (NASDAQ:GLTO) and Pasithea Therapeutics (NASDAQ:KTTA) - Defense World
Analyzing Pasithea Therapeutics (NASDAQ:KTTA) and MusclePharm (OTCMKTS:MSLP) - Defense World
KTTA stock touches 52-week low at $2.72 amid market challenges - Investing.com Nigeria
KTTA stock touches 52-week low at $2.72 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $2.87 amid market challenges - Investing.com Nigeria
Pasithea Therapeutics Announces Positive Safety Review Committee Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
Pasithea's PAS-004 Drug Shows Strong Safety Profile in Phase 1 Trial, Zero Toxicity Issues | KTTA Stock News - StockTitan
Pasithea Therapeutics (NASDAQ:KTTA) Shares Up 2.4% – Still a Buy? - Defense World
KTTA stock touches 52-week low at $3.19 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $3.19 amid market challenges - Investing.com UK
ARMISTICE CAPITAL, LLC Acquires New Stake in Pasithea Therapeuti - GuruFocus.com
Finanzdaten der Pasithea Therapeutics Corp-Aktie (KTTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):